(MENAFN- EIN Presswire)
Spine Biologics Market
Advancements in Personalized Medicine, Stem Cell Therapy, and Technological Innovations Drive market Growth.
AUSTIN, TX, UNITED STATES, November 27, 2024 /EINPresswire / -- The Global Spine Biologics Market was valued at USD 3.02 billion in 2023 and is projected to grow to USD 4.73 billion by 2032, expanding at a CAGR of 5.13% during the forecast period from 2024 to 2032.
The demand for innovative spinal care solutions is on the rise due to the market's continued ascent with advancements in personalized
medicine and advancement in minimally invasive surgical techniques. Some of the impressive, well-executed awareness campaigns regarding the effectiveness of regenerative therapies, such as stem cell treatments and platelet-rich plasma (PRP), are gaining a hold on treatments for many spinal disorders. In addition, the super-aging population is a primary driver for conditions such as degenerative disc disease, osteoarthritis, and spinal stenosis, creating a demand for biological solutions to enhance patient outcomes and quality of life.
New surgical procedures such as Extreme Lateral Interbody Fusion (XLIF) also are further accelerating growth. "A Report by the Barrow Neurological Institute, May 2023" claims that XLIF is a minimally invasive lumbar spinal fusion procedure with many advantages such as low blood loss, short recovery times, and minimal surgical pain. It is increasingly adopted for diseases like lumbar spinal stenosis, mild scoliosis, and degenerative disc disease, indicating the importance of advanced biologics in modern spinal surgeries.
Get a Free Sample Report of Spine Biologics Market @
Key Spine Biologics Market Players:
Orthofix
DePuy Synthes (Johnson & Johnson)
Exactech Inc.
Arthrex Inc.
Medtronic
Stryker
NuVasive Inc.
Organogenesis Inc.
Kuros Biosciences
Zimmer Biomet
others players
Market Analysis
The rise of spinal disorders, mainly due to an aging population, is quite in line with the perpetuation of this market. Aging often leads to degeneration of the spine, characterized by decreased bone density, elasticity of the cartilage, and disc height. This condition progresses to osteoarthritis, degenerative disc disease, and spinal stenosis, conditions that generate a lot of pain and restriction in the mobility of patients.
Biologics, including stem cell therapies and PRP, present innovative solutions to these challenges. These alternatives can regenerate spinal discs that have been worn out while PRP can decrease inflammation and hasten healing. Increasingly, a growing aged population worldwide will need these advanced treatments, which translates into vast implications for quality-of-life improvements.
With an increase in the incidence of spinal conditions, research and innovation in biologics will be on the cards to cover the rising volume of patients who are affected by such conditions. Developing efficient, minimally invasive treatments underlines better patient outcomes and the challenges of aging populations.
Segment Analysis
By Product
In 2023, the spinal allografts segment dominated the market with 59% of the total revenue. This is due to their osteoconductive properties, which provide immediate structural support without the need for a second surgery to obtain the bone, thus shortening the duration of surgery as well as recovery rates.
By End-use:
Hospitals dominated the end-use segment with a 62% share in 2023. This leadership is driven by the high volume of spinal fusion surgeries performed in hospital settings, supported by the presence of advanced facilities like George Washington University Hospital and Massachusetts General Hospital.
Need any customization research on Spine Biologics Market, Enquire Now @
Key Market Segments
By Product
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Bone Graft Substitutes
Bone Morphogenetic Proteins
Synthetic Bone Grafts
Cell-base Matrix
By End-use
Hospitals
Ambulatory Surgical Centers
Regional Insights
North America
North America dominated the market with the largest market share in 2023 at 49%. This is mainly due to factors such as stable economic growth, rapid adoption of minimally invasive surgeries, and increasing prevalence of spinal disorders, including disc-related issues and spinal stenosis. Developed healthcare infrastructure and highly paced research initiatives contribute significantly to its leadership in the market.
Asia-Pacific:
Asia-Pacific is the fastest-growing region, supported by a huge patient population, rapid awareness of biologics among patients and surgeons, and significant advances in healthcare infrastructure. Moreover, health care expenditure is also rising in association with a high incidence of spine injuries, mostly road accidents in the region, thus supporting growth in the region.
Recent Developments
DePuy Synthes (August 2024): The firm launched its first active spine robotics and navigation platform, combined with the VELYSTM Enabling Technologies Portfolio. Such a dual-use robotics and navigation system does appear to focus on enhancing the precision of spinal surgeries and supplementing existing J&J MedTech Spine products.
Orthofix Medical Inc. October 2023 Orthofix Medical Inc. announced the company's full commercial launch of OsteoCove, an advanced bioactive synthetic graft cleared by the FDA for orthopedic and spine procedures. Coming in strip and putty formats, this innovative graft accelerates bone healing for better surgical results.
Buy Full Research Report on Spine Biologics Market 2024-2032 @
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter's Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients
6. Competitive Landscape
7. Spine Biologics Market by Product
8. Spine Biologics Market by End-use
9. Regional Analysis
10. Company Profiles
11. Use Cases and Best Practices
12. Conclusion
Speak with Our Expert Analyst Today to Gain Deeper Insights @
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Akash Anand
SNS Insider Pvt. Ltd
415-230-0044
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN27112024003118003196ID1108931698